creating the path for innovative new therapies raymond l. woosley, md, phd
DESCRIPTION
Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD President, The Critical Path Institute. Goals. Overview of the PDUFA Impact Critical Path Initiative Purpose of the Critical Path Institute 4. A model for new relationships 5. Proposal for a PDUFA initiative. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/1.jpg)
Creating the Path for Innovative New Therapies
Raymond L. Woosley, MD, PhD
President, The Critical Path Institute
![Page 2: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/2.jpg)
Goals1. Overview of the PDUFA Impact
2. Critical Path Initiative
3. Purpose of the Critical Path Institute
4. A model for new relationships
5. Proposal for a PDUFA initiative
![Page 3: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/3.jpg)
CDER NME Median Approval Times by Calendar Year
0.0
10.0
20.0
30.0
40.0
50.0
Med
ian
Ap
pro
val T
ime
(Mo
nth
s)
Standard (1992 - 2003)Type C (1981 -1991)
Priority (1992 - 2003)Type A or B (1981 -1991)
* Prior to 1992, therapeutic gain was classified as type A, B, or C (defined below). Starting in 1992 Priority and Standard designation was used to represent therapeutic potential for new drug approvals.
FDA Review Efficiency Has Increased…
![Page 4: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/4.jpg)
Product Approvals Increased Transiently…
No.
of
Dru
gs
Ap
pro
ved
Sources: Washington Analysis, LLC and PhRMA for 1990-2000; PhRMA website for 2001-2
0
10
20
30
40
50
60
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
0
5
10
15
20
25
30
35
Approvals
![Page 5: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/5.jpg)
NMEs Filed by Fiscal Year
0
10
20
30
40
50
Nu
mb
er F
iled
Priority Standard
* for NMEs submitted prior to 1992, type A and type B applications are counted as Priority review and type C applications are counted as Standard review.
New Drug Submissions Increased Transiently…
![Page 6: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/6.jpg)
US Pharmaceutical R&D
Total NIH Budget
10 year Trend in Biomedical R&D Spending
![Page 7: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/7.jpg)
New Drug Applications
New Biological Applications
10 year Trend in New Applications to FDA
![Page 8: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/8.jpg)
Success Rates Remain Low
Nature Reviews: Drug Discovery, 3 (8): 711, 2004
![Page 9: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/9.jpg)
The Critical Path InitiativeThe Critical Path Initiative
![Page 10: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/10.jpg)
CPI calls for Innovations and Collaboration in the Development Phases
Critical Path to MarketDiscovery
![Page 11: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/11.jpg)
Response to CPIOverwhelming support:
Industry (Internal CPI task forces)
NIH Collaborations (NCI, NHGRI)
The Critical Path Institute
Academia CDDS and JETS at UCSF
MIT Center for Biomed. Innovation
ISIS at Indiana Univ.
ECG Warehouse at Duke Univ.
NIPTE (11 univ. manufacturing partners)
![Page 12: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/12.jpg)
Why “Critical Path Institute”Why “Critical Path Institute”
![Page 13: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/13.jpg)
C-Path Vision and Mission
A non-profit, publicly-funded Institute that serves as a “neutral ground” for scientists from the FDA, academia and the pharmaceutical industry to accelerate the development of safe medical products.
C-Path will develop tools not drugs
![Page 14: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/14.jpg)
The NCFST is a unique research consortium composed of scientists from academia, the FDA and food-related industries. The Center provides a neutral ground where industry, academia and the FDA scientists address food safety issues.
A proven concept……..
Moffett Center, U. Illinois, Chicago
Neutral Ground
![Page 15: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/15.jpg)
C-Path Programswww.C-Path.org
SMARTERFASTER
SAFER
![Page 16: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/16.jpg)
Toxicogenomic Cross-Validation Consortia
• Pharmaceutical companies have created innovative tests to predict drug toxicity
• Data from these tests cannot be submitted as evidence of safety for new drugs because they have not been “independently validated”
• Companies will disclose their methods so they can test and validate one another’s methods
• Focus areas: liver, kidney, muscle, nerve
• C-Path will gather the data and submit to FDA
![Page 17: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/17.jpg)
Toxicogenomic Cross-Validation Consortia
Company• “A”• “B”• “C”• “D”• “E”• “F”
• FDA• SRI• UA• TGen• Pharmaceutical
Consortium
![Page 18: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/18.jpg)
Basic Principles:
• Publicly funded, no direct funding from medical product companies
• Industry consortia funding is possible with transparency and oversight
• Project Specific consortia funding
• Oversight Board
• FDA
• Industry
• Consumer/Patient Representatives
C-Path: “Neutral Territory”
![Page 19: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/19.jpg)
• Lack of funding for FDA participation
• Lack of funding for method development and validation
• Lack of process to prioritize and coordinate CPI activities
• Lack of “laboratory” for testing new methods, biomarkers, etc
Major Impediments for CPI
![Page 20: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/20.jpg)
• Small percent increase in PFUFA fees for FDA/CPI
• Match from Congressional appropriations
A Proposal to Advance Drug Development:
1. FDA Funding for CPI
![Page 21: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/21.jpg)
• Industry consortia operating with FDA advisors on “neutral ground”
• PDUFA grants/contracts for work mutually agreed upon by CPI Steering Committee
A Proposal to Advance Drug Development:
2. Funding for Methods Development/Validation
![Page 22: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/22.jpg)
Moffett Center Model• FDA representatives• Industry representatives• Consumer/Patient reps• Independent
scientists/experts
A Proposal to Advance Drug Development:
3. CPI Steering Committee
![Page 23: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/23.jpg)
• Life threatening illnesses• Orphan drug development
(Congressionally mandated to assist in development)
• Personalized medicine
A Proposal to Advance Drug Development:
4. CPI Testing Environment
![Page 24: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/24.jpg)
The regulators and the regulated need “neutral ground” where they can work together to improve the process of drug development.
PDUFA could be the catalyst for change.
Summary
![Page 25: Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD](https://reader035.vdocuments.mx/reader035/viewer/2022070419/56815ca2550346895dcaa8a3/html5/thumbnails/25.jpg)
Thank You!